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Marcelo Cury, Roy K. Greenberg, Jose P. Morales, Walid Mohabbat, Adrian V.
Hernandez
Purpose: Aneurysms involving the supra-aortic vessels are rare but carry
serious risk of embolization, thrombosis, and rupture. We describe our expe-
rience with the diagnosis, treatment strategies, and outcomes in patients
with extended follow-up.
Methods: Data during a 17-year period (January 1990 to December 2007)
was analyzed. We assessed age, gender, presenting symptoms, localization,
pathologic diagnosis, type of procedures, complications, and survival.
Results: A total of 74 patients were treated for supra-aortic aneurysms. Of
all aneurysms treated, 63% were degenerative, 24% iatrogenic, 8% trau-
matic, 3% genetic, and 1% mycotic. The subclavian artery was most
commonly affected (50%, 2/3 in the right side), followed by the common
carotid (36%), internal carotid (10%), innominate (3%), and vertebral (1%).
At the time of diagnosis, 52 patients (70%) were asymptomatic, but of those
symptomatic 68% had an embolic event as a presenting symptom. Embolic
episodes were more common in patients with smaller aneurysms (P < .006).
Open surgery was performed in 77% of all cases, and the use of endovascular
techniques became the predominant treatment modality over the last 4 years.
Survival at 30 days was 100%. Five- and 10-year survival rates were 87% and
43%, respectively.
Conclusion: Most cases of supra-aortic aneurysm are asymptomatic and
embolization as opposed to rupture represents the greatest risk to the
patient. Most cases can be detected prior to symptoms. Endovascular repair
is an emerging alternative of treatment and, with the current development
of appropriate devices, will likely form the mainstay of therapy in the near
future.Complications of spinal fluid drainage in thoracoabdominal aortic
aneurysm repair: A report of 486 patients treated from 1987 to 2008
Martha M. Wynn, Matthew W. Mell, Girma Tefera, John R. Hoch, Charles W.
Acher
Objective: Spinal fluid drainage reduces paraplegia risk in thoracic (TAA)
and thoracoabdominal (TAAA) aortic aneurysm repair. There has not been
a comprehensive study of the risks of spinal fluid drainage and how these
risks can be reduced. Here we report complications of spinal fluid drainage
in patients undergoing TAA/TAAA repair.
Methods: The study comprised 648 patients who had TAA or TAAA repair
from 1987 to 2008. Spinal drains were used in 486 patients. Spinal fluid pres-
sure was measured continuously, except when draining fluid, and was
reduced to <6 mm Hg during thoracic aortic occlusion and reperfusion. After
surgery, spinal fluid pressure was kept <10 mm Hg until patients were awake
with normal leg lift. Drains were removed 48 hours after surgery. Spinal and
head computed tomography (CT) scans were performed in patients with
bloody spinal fluid or neurologic deficit. We studied the incidence of head-
ache treated with epidural blood patch, infection, bloody spinal fluid, intra-
cranial and spinal bleeding on CT, as well as the clinical consequences.
Results: Twenty-four patients (5%) had bloody spinal fluid. CT exams showed
seven had no evidence of intracranial hemorrhage, 14 (2.9%) had intracranial* Full articles available online at www.jvascsurg.org
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doi:10.1016/S1078-5884(08)00611-4blood without neurologic deficit, and three with intracranial bleeding and
cerebral atrophy had neurologic deficits (1 died, 1 had permanent hemipar-
esis, and 1 with transient ataxia recovered fully). Two patients without
bloody spinal fluid or neurologic deficit after surgery presented with neuro-
logic deficits 5 days postoperatively and died from acute on chronic subdural
hematoma. Neurologic deficits occurred after spinal fluid drainage in 5 of
482 patients (1%), and 3 died. The mortality from spinal fluid drainage
complications was 0.6% (3 of 482). By univariate and multivariate analysis,
larger volume of spinal fluid drainage (mean, 178 mL vs 124 mL, P < .0001)
and higher central venous pressure before thoracic aortic occlusion (mean,
16 mm Hg vs 13 mm Hg, P < .0012) correlated with bloody spinal fluid.
Conclusion: Strategies that reduce the volume of spinal fluid drainage but
still control spinal fluid pressure are helpful in reducing serious complica-
tions. Patients with cerebral atrophy are at increased risk for complications
of spinal fluid drainage.Risk-adjusted 30-day outcomes of carotid stenting and endarterectomy:
Results from the SVS Vascular Registry
Anton N. Sidawy, Robert M. Zwolak, Rodney A. White, Flora S. Siami, Marc L.
Schermerhorn, Gregorio A. Sicard
Objective: As the first operational societal registry of carotid procedures,
the Outcomes Committee of the Society for Vascular Surgery (SVS) devel-
oped the Vascular Registry (VR) in response to the Centers for Medicare
and Medicaid Services’ (CMS) National Coverage Decision on carotid artery
stenting (CAS). Although CMS requires data submission only on CAS, the VR
collects similar data on carotid endarterectomy (CEA) to allow comparison
of outcomes, as well as potential for expansion to other procedures.
Methods: SVS-VR on-line provider-reported data include baseline through
follow-up visits to better understand long-term risks and benefits associated
with CAS and CEA. The primary outcomes are combined death, stroke, and
myocardial infarction (MI). An independent data coordinating center main-
tains the database, which is Health Insurance Portability and Accountability
(HIPAA)-compliant and auditable.
Results: As of December 26, 2007, 6403 procedures with discharge data
were entered by 287 providers at 56 centers on 2763 CAS patients (1450 with
30-day outcomes, 52.5%) and 3259 CEA patients (1368 with 30-day outcomes,
42%). Of the total cohort, 98% of CEA and 70.7% of CAS (P < .001) were per-
formed for atherosclerotic disease. Restenosis accounted for 22.3% and post-
radiation induced stenosis in 4.5% of CAS patients. Preprocedure lateralizing
neurologic symptoms were present in a greater proportion of CAS patients
(49.2%) than CEA patients (42.4%, P < .001). CAS patients also had higher
preprocedure prevalence of coronary artery disease (CAD), MI, congestive
heart failure (CHF), chronic obstructive pulmonary disease (COPD), and
cardiac arrhythmia. For CAS, death/stroke/MI at 30 days was 7.13% for
symptomatic patients and 4.60% for asymptomatic patients (P = .04). For
CEA, death/stroke/MI at 30 days was 3.75% in symptomatic patients and
1.97% in asymptomatic patients (P = .05). After risk-adjustment for age,
history of stroke, diabetes, and American Society of Anesthesiologists
(ASA) grade (ie, factors found to be significant confounders in outcomes
using backwards elimination), logistic regression analysis suggested better
outcomes following CEA. There were no statistically significant differences
when examining CAS outcomes based on center volume. CAS in athero-
sclerotic disease had significantly worse outcomes than in nonatherosclero-
tic stenosis. When CAS and CEA were compared in the treatment of
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procedures was more pronounced, with death/stroke/MI 6.42% after CAS
vs 2.62% following CEA, P < .0001.
Conclusion: Following best possible risk adjustment of these unmatched
groups, symptomatic and asymptomatic CAS patients had significantly higher
30-day postprocedure incidence of death/stroke/MI when compared with
CEA patients. The initial 1.5 years of data collection provide proof of
concept that a specialty society based VR can succeed in meeting regulatory
and scientific goals. With continued enrollment and follow-up, analysis of
SVS-VR will supplement randomized trials by providing real-world compari-
sons of CAS and CEA with sufficient numbers to serve as an outcome assess-
ment tool of important patient subsets and across the spectrum of
peripheral vascular procedures.Two-year randomized prospective comparison of percutaneous ePTFE/
nitinol self-expanding stent graft vs prosthetic femoral-popliteal bypass
in the treatment of superficial femoral artery occlusive disease
Karen McQuade, Dennis Gable, Stephen Hohman, Greg Pearl, Brian Theune
Background: A randomized prospective study comparing the treatment of
superficial femoral artery occlusive disease percutaneously with an
expanded polytetrafluoroethylene (ePTFE)/nitinol self-expanding stent
graft (stent-graft) vs surgical femoral to above knee popliteal artery bypass
with synthetic graft material.
Methods: One hundred limbs in 86 patients with superficial femoral artery
occlusive disease were evaluated fromMarch 2004 to May 2005. Patient symp-
toms included both claudication and limb threatening ischemia with or
without tissue loss. The TransAtlantic InterSociety Consensus (TASC) II A (N =
18), B (N = 56), C (N = 11), and D (N = 15) lesions were included. Patients were
randomized prospectively into one of two treatment groups; a percutaneous
treatment group (group A; N = 50) with angioplasty and placement of one or
more stent-grafts or a surgical treatment group (groupB;N= 50)with a femoral
to above knee popliteal artery bypass using synthetic conduit (Dacron graft or
ePTFE). Patients were followed for a total of 24 months. Follow-up evaluation
included clinical assessment and physical examination, ankle-brachial indices
(ABI), and color flow duplex sonography at 3, 6, 9, 12, 18, and 24 months.
Results: The mean total lesion length of the treated arterial segment in the
stent-graft group was 25.6 cm (SD  15 cm). The stent-graft group demon-
strated a primary patency of 81%, 72%, and 63% with a secondary patency
of 86%, 83%, and 74% at 6, 12, and 24 months, respectively. The surgical
femoral-popliteal group demonstrated a primary patency of 84%, 77%, and
64% with a secondary patency of 89%, 86%, and 76% at 6, 12, and 24 months,
respectively. No statistical difference was found between the two groups
with respect to primary (P = .716) or secondary patency (P = .695). Grouping
of less severe (TASC II A/B) vs more severe (TASC II C/D) lesions demon-
strated patency at 24 months for the femoral-popliteal arm of 63% and
67%, respectively while that of the stent-graft arm was 64% and 47%, respec-
tively. Secondary patency was 76% in both TASC classifications for the
femoral-popliteal arm with 78% and 47% patency found respectively in the
stent-graft group. These resulted in no significant difference for primary
(P = .978) or secondary (P = .653) patency overall, although there is a trend
for decreased patency with higher TASC II lesions.
Conclusion: Management of superficial femoral artery occlusive disease
with percutaneous stent-grafts exhibits similar primary patency at 24-month
follow-up when compared with conventional femoral-popliteal artery bypass
grafting with synthetic conduit. This treatment method may offer an alter-
native to treatment of the superficial femoral artery segment for revascular-
ization when prosthetic bypass is being considered or when autologous
conduit is unavailable.Predictors of failure after angioplasty of infrainguinal vein bypass grafts
Hector F. Simosa, Frank B. Pomposelli, Suzanne Dahlberg, Salvatore T. Scali,
Allen D. Hamdan, Marc L. Schermerhorn
Objective: Percutaneous transluminal angioplasty (PTA) has had an expand-
ing role as primary therapy for vein graft stenosis with variable results. The
aim of this study is to identify patient and graft characteristics predictive of
failure after PTA of infrainguinal vein grafts.
Methods: Retrospective review from Jan 2004 to Mar 2007 of patients under-
going angioplasty for failing grafts. Demographics, comorbidities, procedural
data, and follow-up information were recorded. PTA failure was defined asfirst significant event including restenosis by duplex scan (>3.5  velocity
ratio), occlusion, redo-PTA, surgical revision, or amputation. Descriptive,
logistic regression and life-table analyses were performed.
Results: Eighty-seven grafts in 79 patients underwent PTA. Mean age was 70
years (median 70; range, 39-89 years), 71% were male and 52% were symp-
tomatic (40% with limb-threat). Mean follow-up was 17 months (median
17.4; range, 0.03-39.8 months). Freedom from PTA failure was 58% (standard
error [SE] 0.0574) at 12 months. Predictors of PTA failure by multivariate
analysis were: time from bypass <3 months (hazard ratio [HR] 5.8; 95% confi-
dence interval [CI] 1.91-18.0; P = .002), stenosis length >2 cm (HR 2.7; 95%
CI 1.33-5.83; P = .007) and multiple stenoses (HR 2.5; 95% CI 1.29-5.1; P =
.007). PTA patency for grafts with favorable lesions (single, less than 2 cm
lesions in grafts older than 3 months) was 71% vs 35% for unfavorable lesions
at 12 months. Limb-salvage was 95% and 90% and overall survival was 92%
and 81% at 12 and 24 months, respectively.
Conclusion: PTA of failing infrainguinal vein grafts is a reasonable primary
therapy for favorable lesions. Early graft stenosis, long, and multiple
stenoses are markers for procedural failure and are better served with
surgical revision.Neovalve construction in deep venous incompetence: Comparison
between two subsequent case series and related technical details
Marzia Lugli, Sara Guerzoni, Mariano Garofalo, Gianluca Smedile, Oscar
Maleti
Objectives: The purpose of this study is to assess the outcome of neovalve
construction in two consecutive series of patients affected by postthrombo-
tic syndrome and valve agenesis. The technique was modified in the second
series so as to correct a cause of failure.
Methods: Between December 2000 and June 2007, 40 neovalve constructions
were carried out in 36 patients (19 males, 17 females, median age 57, range,
29-82) affected by deep venous insufficiency. Thirty-two patients were
affected by postthrombotic syndrome and 4 by valve agenesis. The 32 patients
with postthrombotic syndrome were selected from among 76 patients with
resistant ulcers classified C 6,S E S A S,D,P P R,RO and the 4 patients with valve
agenesis were selected from among 28 affected by resistant ulcers classified
asC 6,S E CA S,D,P P R. The patientswere subdivided into 2 groups. Thefirst group
included 19 operations performed in the period between December 2000 and
December 2004, with a median follow-up of 54 months (range, 31-78). The
second group included 21 patients operated on between January 2005 and
June 2007, with a median follow-up of 5 months (range, 2-29). In the second
group, a surgical variation was applied in order to prevent flap collapse and
to maintain the continence of the neovalve.
Results: In the first series, ulcer healing was observed in 16 cases out of 19
(84%). Recurrent ulcers were observed in one case after 3 years. Valve
competence was ascertained in 13 cases per 803 patient-months (1.6/100
patient-months). With regard to the second series, competence was
achieved in all cases with a cumulative rate of 21 per 228 patient-months
(9.2/100 patient-months). In the second series, the ulcer failed to heal in
one case and recurred in two cases, with an intention-to-treat ulcer recur-
rence rate of three cases per 209 patient-months. Postoperative deep-
venous thrombosis was observed in 3 patients in the first series. None was
detected in the second series. The mortality rate was 0 and in neither group
was pulmonary embolism detected.
Conclusion: The modified technique applied to the second group seemed to
improve valve continence results significantly. However, a longer follow-up
period is required for the latter group to validate this technical enhancement.Technique for subclavian to carotid transposition, tips, and tricks
Mark D. Morasch
When performed properly, a transposition is the most efficient and most
durable procedure for reconstructing the subclavian artery for proximal
occlusive disease or to extend the landing zone in the aortic arch prior to en-
dovascular therapy for thoracic aortic pathology. The proximal subclavian
artery, on the right or on the left, is approached quite differently than it
is for a bypass procedure. The technique is described in detail here. There
are very few contraindications to transposition, the advantages over the
alternate options are many, and it can be the approach of choice in the vast
majority of patients.
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A.F.H. Stalenhoef
There is overwhelming evidence that statins reduce morbidity and mortality
in patients with coronary disease. Statins have also been shown to reduce
the risk of (recurrent) stroke. LDL-cholesterol, which plays a causal role in
the development of atherosclerotic disease, is the primary lipid target in
prevention and is effectively reduced by these agents. In this review, studies
are summarized addressing the issues whether statins also directly influencethe atherosclerotic process in peripheral arterial disease, carotid artery
stenosis, and growth of abdominal aortic aneurysms and whether statins
have an effect on perioperative outcomes in vascular surgery patients. It
appears that the evidence of statins on peripheral arterial disease is scarce
and effect on perioperative outcome inconclusive. Prospective randomized
trials to answer these questions cannot be performed anymore, however,
because all vascular patients should receive statin treatment as secondary
prevention of cardiovascular disease.
